NCT02970981View on ClinicalTrials.gov

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

May 2, 2022

Conditions
Melanoma
Interventions
BIOLOGICAL

Nivolumab

BIOLOGICAL

Ipilimumab

Trial Locations (1)

10016

Laura and Isaac Perlmutter Cancer Center, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

NYU Langone Health

OTHER